<DOC>
	<DOCNO>NCT01402297</DOCNO>
	<brief_summary>The aim study investigate effect inhale apocynin ROS ( reactive oxygen specie ) NOS ( reactive nitrogen specie ) synthesis 13 COPD patient . Effects nebulized apocynin ( 0.5 mg/ml , 6 ml ) assess exhaled breath condensate ( EBC ) 30 , 60 120 minute .</brief_summary>
	<brief_title>Hydrogen Peroxide Nitrite Reduction Exhaled Breath Condensate COPD Patients</brief_title>
	<detailed_description>Apocynin reduce hydrogen peroxide concentration exhale breath condensate 60 120 minute apocynin nebulization compare placebo ( 0.43 μM vs. 0.59 μM 0.41 μM vs. 0.58 μM respectively , p &lt; 0.05 ) . Interestingly , apocynin cause decrease NO2- concentration 30 , 60 120 minute apocynin inhalation ( 3.9 μM vs. 4.5 μM , 3.8 μM vs. 4.5 μM 3.7 μM vs. 4,4 μM respectively , p &lt; 0.05 ) comparing placebo , cause significant change concentration NO3- timepoint ( p &gt; 0.05 ) . No influence apocynin safety parameter , adverse effect observe .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Acetovanillone</mesh_term>
	<mesh_term>Hydrogen Peroxide</mesh_term>
	<criteria>patient suffer bronchial COPD ( II III stage ) patient free medication day research patient suffer infectious disease include upper respiratory tract infection least 3 month prior study Patients suffer GOLD I stage patient take medication day study infectious disease occur 3 month less study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>apocynin</keyword>
	<keyword>COPD</keyword>
</DOC>